FDA Issues Draft Guidance on Drug Development for Major Depressive Disorder

The FDA published draft guidance to assist developers of monotherapeutic, combination and adjunctive drug treatments for major depressive disorder (MDD), offering considerations for nonclinical safety and clinical pharmacology.
Source: Drug Industry Daily